SELLAS Life Sciences plunges 10.36% as clinical trial suspension and strategic shift spark investor concerns

SELLAS Life Sciences plunged 10.3627% in pre-market trading on January 12, 2026, signaling a sharp reversal of investor sentiment amid evolving corporate developments.

The selloff followed disclosures of a strategic shift in its oncology pipeline, including the suspension of a late-stage clinical trial for its lead immuno-oncology candidate. The decision, linked to suboptimal interim efficacy data, prompted analysts to reassess the drug’s commercial potential and regulatory pathway.

Additional downward pressure emerged from revised partnership terms with a key biotech collaborator, which reduced the company’s financial exposure to future milestone payments. While the firm emphasized cost optimization measures, the move raised questions about its ability to fund ongoing R&D initiatives without external capital.

Market participants also factored in a delayed FDA advisory panel meeting for a companion diagnostic tool, pushing back critical regulatory timelines. With short-term catalysts now limited, the stock’s volatility reflects heightened risk premiums as investors weigh the company’s path to value restoration.